• NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) is set to release its quarterly earnings with analysts projecting a negative EPS of -$0.09 and revenue of $1.33 million.
  • The company currently exhibits challenging financial metrics, including a negative trailing price-to-earnings (P/E) ratio of -2.48 and a negative Enterprise Value to Operating Cash Flow ratio of -3.30, indicating unprofitability and cash consumption.
  • Positive regulatory news from the U.S. Food and Drug Administration (FDA) regarding its preservative-free ketamine has "substantially de-risked" the path to approval, with only a manufacturer certification pending.

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company. The company is scheduled to release its quarterly earnings report on August 17, 2026. Wall Street analysts expect an earnings per share (EPS) of -$0.09 on projected revenue of approximately $1.33 million for the quarter.

Currently, NRx Pharmaceuticals' financial data shows a negative trailing price-to-earnings (P/E) ratio of -2.48. A negative P/E ratio indicates that the company has not been profitable over the past year. This is further supported by a negative earnings yield of approximately -23.81%, showing a loss relative to its share price.

The company's valuation metrics include a Price-to-Sales ratio of 24.03. However, its Enterprise Value to Operating Cash Flow ratio is negative at -3.30. This negative figure points to the company using more cash in its core business operations than it generates, resulting in a negative cash flow.

Recent developments provide important context. As highlighted by GlobeNewswire, the U.S. Food and Drug Administration (FDA) completed its first-cycle review of NRx Pharmaceuticals' preservative-free ketamine. The review identified no major deficiencies related to the drug, which the company states "substantially de-risks the path to approval and commercialization."

The only remaining item for approval is a manufacturer certification for a luer lock vial. Following a meeting, the FDA committed to reviewing the certification in the shortest possible cycle. NRx Pharmaceuticals will host a conference call on August 10, 2026, to discuss the regulatory update and its commercial plans.